Partial Compliance and Patient Consequences in Schizophrenia: Our Patients Can Do Better. [CME]
J Clin Psychiatry 2003;64:1308-1315
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The primary objective of this review
is to evaluate the strategies used to improve patient compliance
with antipsychotic medication in the treatment of schizophrenia.
Data Sources: An electronic literature search of
relevant studies using MEDLINE and the Cochrane Library (January
1974-December 2002) was performed using the search terms adherence, antipsychotic, atypical, compliance, conventional,
Study Selection: English-language and
non-English-language articles, references from bibliographies of
reviews, original research articles, and other articles of
interest were reviewed.
Data Extraction: Data quality was determined by
publication in the peer-reviewed literature and the most
important information was identified.
Data Synthesis: Atypical antipsychotics are
associated with an improved side-effect profile and reduced risk
of relapse compared with the older agents. Additional benefit may
be provided by long-acting injectable formulations as they
provide the confidence of continuous medication coverage.
Conclusions: Successful treatment of patients
with schizophrenia requires acknowledgment that partial
compliance will present a major barrier to achieving maximum
outcomes. Ideally, all patients suspected of partial compliance
should be considered suitable for treatment with a long-acting
injectable atypical antipsychotic.